A practical reference on GRF(1-29): what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
This page was last updated on 2026-07-04 and is reviewed periodically as new material appears.
The peptide binds GHRH receptors on somatotroph cells within the anterior pituitary, triggering a signalling cascade that increases growth hormone secretion. Its improved resistance to dipeptidyl peptidase IV degradation distinguishes it from the parent hormone. In the DAC-bearing version, a maleimide group reacts with a cysteine residue on serum albumin, forming a covalent bond that keeps the peptide in circulation far longer. That albumin attachment is the central design feature separating the two research variants.
Pharmacokinetic behaviour differs sharply between the two forms. The DAC-bearing peptide shows an extended circulation time measured in days, whereas the version without the complex is cleared within roughly half an hour. This gap shapes how researchers design dosing schedules in animal models. Whether the prolonged presence of the DAC form produces effects meaningfully different from the short-acting variant remains an open question, since comparative human data are scarce.
CJC-1295 is a synthetic peptide designed to mimic growth hormone-releasing hormone (GHRH), the endogenous signal that prompts the pituitary gland to release growth hormone. The compound is a modified fragment of the natural hormone, spanning the first twenty-nine amino acids of GHRH with several substitutions that slow enzymatic breakdown. Two variants circulate in research settings: one carrying a drug affinity complex (DAC) and one without it. The DAC-free form is frequently labelled Mod GRF(1-29) in catalogs and discussion forums.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
| Property | Value | Notes |
|---|---|---|
| Molecular weight (with DAC) | ~3647 Da | Calculated from the full amino acid sequence |
| Molecular weight (without DAC) | ~3368 Da | Mod GRF(1-29) variant |
| Appearance | White lyophilized powder | Typical form supplied for research |
| Solubility | Soluble in water | Dissolves in aqueous buffers |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
White Rhodesian officers and non-commissioned officers left the colony in September and October 1939 to command units of black Africans in the west and east of the continent, with most joining the Royal West African Frontier Force (RWAFF) in the Colony of Nigeria, the Gold Coast and neighbouring colonies. The deployment of white Rhodesian officers and NCOs to command black troops from elsewhere in Africa met with favour from the military leadership and became very prevalent.
Polymyalgia rheumatica (PMR) is a systemic inflammatory disease characterized by pain or stiffness, usually in the neck, shoulders, upper arms, and hips, but which may occur all over the body. Almost all cases occur in people age 50 or older. Pain and stiffness of PMR is worse in the morning and improves throughout the day, but these symptoms frequently persist to some extent throughout the day and into the evening. People who have polymyalgia rheumatica may also have temporal arteritis (giant cell arteritis), an inflammation of blood vessels in the face which can cause blindness if not treated quickly. The pain and stiffness can result in a lowered quality of life, and can lead to depression. The exact cause of PMR, including whether or not it may be an autoimmune disease, is unclear. Persons of Northern European descent are at greater risk. There is no definitive laboratory test, but C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR) can be useful as non-specific markers of systemic inflammation. PMR is usually treated with corticosteroids taken by mouth. Most people need to continue the corticosteroid treatment for two to three years. PMR sometimes goes away on its own in a year or two, but medications and self-care measures (e.g., eating the recommended amount of fruits and vegetables) can improve the rate of recovery. PMR was first established as a distinct disease in 1966 by a case report on 11 patients at Mount Sinai Hospital in New York City. It takes its name from the Greek word Πολυμυαλγία polymyalgia, which means "pain in many muscles".
The red-bellied black snake (Pseudechis porphyriacus) is a venomous species native to Australia. The venom of the red-bellied black snake consists of myotoxins, coagulants and also has haemolytic and cytotoxic properties. It also contains weak pre-synaptic neurotoxins. The murine LD50 is 2.52 mg/kg SC. Average venom yield per bite is 37 mg and a maximum yield of 97 mg. Bites from red-bellied black snake are rarely life-threatening due to the snake usually choosing to inject little venom toxin, but are still in need of immediate medical attention. Rate of envenomation is 40–60%, but the untreated mortality rate is less than 1%.
Sources: en.wikipedia.org
== Presentation == Patients usually begin to notice symptoms in their 30s and the course is usually slowly progressive. Common features include peripheral neuropathy, cardiomyopathy, and hemolytic anemia. Other features include limb chorea, facial tics, other oral movements (lip and tongue biting), seizures, a late-onset dementia, and behavioral changes.
Blended leaf (BL) sheet: A thin, dry sheet cast from a paste made with tobacco dust collected from tobacco stemming, finely milled burley-leaf stem, and pectin. Reconstituted leaf (RL) sheet: A paper-like material made from recycled tobacco fines, tobacco stems and "class tobacco", which consists of tobacco particles less than 30 mesh in size (about 0.6 mm) that are collected at any stage of tobacco processing. RL is made by extracting soluble chemicals in tobacco byproducts, processing the leftover tobacco fibers from the extraction into a paper, and then reapplying the extracted materials in concentrated form onto the paper in a fashion similar to paper sizing. At this stage, ammonium additives are applied to make reconstituted tobacco an effective nicotine delivery system. Expanded (ES) or improved stem (IS): Expanded stem is rolled, flattened, and shredded leaf stems that are expanded by being soaked in water and rapidly heated. Improved stem follows the same process, but is simply steamed after shredding. Both products are then dried. These products look similar in appearance, but are different in taste. According to data from the World Health Organization, the amount of tobacco per 1000 cigarettes fell from 1.03 kg (2.28 pounds) in 1960 to 0.41 kg (0.91 pounds) in 1999, largely as a result of reconstituting tobacco, fluffing, and additives. A recipe-specified combination of brightleaf, burley-leaf, and oriental-leaf tobacco is mixed with various additives to improve its flavors.
==== Alkaline phosphatase ==== Alkaline phosphatase from E. coli can be purified using a DEAE-Cellulose matrix. A. phosphatase has a slight negative charge, allowing it to weakly bind to the positively charged amine groups in the matrix. The enzyme can then be eluted out by adding buffer with higher salt concentrations.
== Manufacturing == Semaglutide has been approved in biologically and chemically synthesized forms. Approval of the original brand-name versions (such as Ozempic) was based on a biologic (recombinant DNA) production process using a genetically-modified yeast (Saccharomyces cerevisiae) to produce a precursor to semaglutide, and subsequent chemical processes (protein purification) to create the active ingredient. Approval of generic versions has instead been based on fully chemical syntheses that yield the same semaglutide molecule from the assembly of amino acids. Compounded drug versions of semaglutide have been created and made widely available, albeit without approval.
Sources: en.wikipedia.org
=== Absorption === The oral bioavailability of CPA is 68 to 100%. The absorption of oral CPA is slow but complete, and the medication is not subject to a significant first-pass effect. The mean absorption half-life of oral CPA is about 1.5 hours. Steady-state levels of CPA occur with oral CPA after about 8 days of continuous administration, with a 2- to 3-fold gradual accumulation in CPA levels. Oral CPA is taken daily and intramuscular CPA is administered weekly or biweekly. Following a single low oral dose of 2 mg CPA in combination with 35 or 50 μg ethinylestradiol in premenopausal women, mean peak levels of CPA of 7.2 to 15.2 ng/mL (17–36.5 nmol/L) have been recorded after 1.6 to 3.7 hours. In healthy men, a single high oral dose of 100 mg CPA produced maximal CPA levels of 254 ng/mL (609 nmol/L) after 2.6 hours. In aged men with prostate cancer, continuous oral CPA therapy resulted in CPA levels of 132 ± 18 ng/mL at 25 mg/day, 246 ± 13 ng/mL at 50 mg/day, and 348 ± 23 ng/mL at 100 mg/day. Similarly, in healthy young women, a single high oral dose of 100 mg CPA resulted in peak CPA levels of 255 ng/mL (612 nmol/L) within 2 to 3 hours. During continuous treatment with high oral doses of CPA in women with hirsutism, levels of CPA were 199 to 228 ng/mL (477–547 nmol/L) with 50 mg/day CPA and were 436 to 520 ng/mL (1050–1250 nmol/L) with 100 mg/day CPA. After a single intramuscular injection of 300 mg CPA in healthy young women, maximal levels of CPA of 191 ng/mL (458 nmol/L) and of 15β-OH-CPA of 164 ng/mL occurred after 2 to 4 days.
Minister for Economic Growth Nicola Willis proposes scrapping several procurement rules including the Living Wage requirement for government contracts. She also proposes a new economic benefits test for both government services and building contracts. The Whanganui District Council scraps its food scraps collection service in response to local opposition. 13 March – The New Zealand Government hosts a two-day Infrastructure Investment Summit in Auckland with the goal of attracting international investment from foreign sovereign funds and multinational companies. Protesters from various groups including ActionStation picket the summit's premises at Park Hyatt. 14 March: Compass Group confirms it will acquire the assets of the bankrupt Libelle Group food catering service. State Highway 1 Desert Road reopens after two months of repairs. 17 March: The Whangārei District Council rescinds its decision in November 2024 to defy a Government directive to fluoridate its water supply, pending a High Court injunction on the matter expected to be released on 18 March. A 14-year-old youth is convicted of the manslaughter of Dunedin teenager Enere McLaren-Taana in May 2024. 19 March – The blobfish (Psychrolutes microporos) is named the 2025 New Zealand Fish of the Year. 20 March – The 2025 New Zealander of the Year Awards are announced, with women's health academic Bev Lawton named New Zealander of the Year. 21 March: Wellington High Court Justice Jason McHerron dismisses a judicial review against Cuba Street's rainbow crossing.
=== Fraction collector === The fraction collector is typically a rotating rack that can be filled with test tubes or similar containers. Distribution of the eluate into separate containers are determined by fixed volumes or specific fractions detected at peaks of protein concentration. Many systems include various optional components. A filter may be added between the mixer and column to minimize clogging. In large FPLC columns the sample may be loaded into the column directly using a small peristaltic pump rather than an injection loop. When the buffer contains dissolved gas, bubbles may form as pressure drops where the buffer exits the column; these bubbles create artifacts if they pass through the flow cells. This may be prevented by degassing the buffers, e.g. with a degasser, or by adding a flow restrictor downstream of the flow cells to maintain a pressure of 1-5 bar in the eluant line.
Sources: en.wikipedia.org
The synthetic peptide keeps the receptor-binding region of GHRH but carries substitutions that resist enzymatic cleavage. In the DAC version, an added group also anchors the molecule to albumin, extending its presence in the bloodstream.
The maleimide group forms a covalent link with albumin, an abundant blood protein. This attachment slows clearance, so a single administration persists much longer than the unmodified peptide. The feature is the main reason the two variants are handled differently in study design.
It is not an approved therapeutic product in major regulatory jurisdictions. It appears in research chemical catalogs and scientific literature rather than pharmacy shelves. Clinical development was limited and did not reach approval.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.